1. Project Clot: Clot Detection Device for Stroke Prevention Team Atriumph: Erica Kim, Angela Li, Sam Vallagomesa, Michael Williams-Hart

2. Background & Motivation Agenda Market & Customer Analysis Design Specifications Moving Forward

3. Atrial Fibrillation Most common type of arrhythmia Affects 3.2 million people in the U.S.

4. Atrial Fibrillation fatigue difficulty breathing dizziness

5. Embolic Stroke in AF Patients Accounts for >15% of all strokes in the U.S No effective method for stroke prevention in AF patients Detection  treatment

6. Left Atrial Appendage (LAA)

7. Embolic Stroke in AF Patients AF Episode Reduced LAA function Blood stasis Clot Formation Regain LAA function Pump out clot Embolic stroke Clot Formation

8. Blood stasis Clot Formation Regain LAA function Pump out clot Embolic stroke Design and test a clot detection & monitoring device to prevent embolic stroke for patients with atrial fibrillation Project Clot Team Atriumph

9. Transesophageal Echocardiogram (TEE) Description Uses high frequency sound waves to produce images of the posterior side of the heart

10. Transesophageal Echocardiogram (TEE) Advantages 100% sensitivity 99% specificity Current standard of care

11. Transesophageal Echocardiogram (TEE) Disadvantages Moderately invasive Expensive Requires skilled technician or cardiologist

12. Description Cardiac Computed Tomography (CT) Uses x-ray to produce cross-sectional images of a scanned object

13. Cardiac Computed Tomography (CT) Advantages 96% sensitivity 92% specificity Non-invasive

14. Cardiac Computed Tomography (CT) Disadvantages Uses radiation Expensive Requires clinical setting

15. Clot Detection Devices are Novel TEE & CT used only before ablation procedure Specifically used for clot detection Permanent implant continuously monitors patient Notifies patient YES or NO to clot formation outside clinical setting Are not monitoring techniques Requires clinical setting

16. Clot Detection Devices are Novel TEE & CT used only before ablation procedure Specifically used for clot detection Permanent implant continuously monitors patient Notifies patient YES or NO to clot formation outside clinical setting Are not monitoring techniques Requires clinical setting

17. Clot Detection Devices are Novel TEE & CT used only before ablation procedure Specifically used for clot detection Permanent implant continuously monitors patient Notifies patient YES or NO to clot formation outside clinical setting Are not monitoring techniques Requires clinical setting

18. Market Analysis Estimated Market SizeWillingness to Pay Predicted Market Share 119,250 patients/year approx. $2,500 15% $45 million/year Estimated Financial Opportunity

19. Market Analysis Estimated Market SizeWillingness to Pay Predicted Market Share 119,250 patients/year approx. $2,500 15% $45 million/year Estimated Financial Opportunity

20. Market Analysis Estimated Market SizeWillingness to Pay Predicted Market Share 119,250 patients/year approx. $2,500 15% $45 million/year Estimated Financial Opportunity

21. Market Analysis Estimated Market SizeWillingness to Pay Predicted Market Share 119,250 patients/year approx. $2,500 15% $45 million/year Estimated Financial Opportunity

22. Market Analysis Estimated Market SizeWillingness to Pay Predicted Market Share 119,250 patients/year approx. $2,500 15% $45 million/year Estimated Financial Opportunity

23. Clinician Patient User COMPANY LOGO Customer Needs Analysis

24. COMPANY LOGO Customer Needs Analysis Accuracy Safety Ease of Use Maintenance Cost

25. COMPANY LOGO Translating Needs to Specs Accuracy Safety Ease of Use Maintenance Cost

26. COMPANY LOGO 90-95% Sensitivity & Specificity Safety Ease of Use Maintenance Cost Translating Needs to Specs

27. COMPANY LOGO Sensitivity & Specificity Safety Ease of Use Maintenance Cost Translating Needs to Specs

28. COMPANY LOGO Sensitivity & Specificity Biocompatible Ease of Use Maintenance Cost Translating Needs to Specs

29. COMPANY LOGO Sensitivity & Specificity Biocompatible Ease of Use Maintenance Cost Translating Needs to Specs

30. COMPANY LOGO Sensitivity & Specificity Biocompatible Maintenance Cost User Friendly Interface Translating Needs to Specs

31. COMPANY LOGO Sensitivity & Specificity Biocompatible Maintenance Cost User Friendly Interface Translating Needs to Specs

32. COMPANY LOGO Sensitivity & Specificity Biocompatible ? Cost User Friendly Interface Translating Needs to Specs

33. COMPANY LOGO Sensitivity & Specificity Biocompatible ? Cost User Friendly Interface Translating Needs to Specs

34. COMPANY LOGO Design Specifications Sensitivity & Specificity Biocompatible User Friendly Interface ? Competitive Pricing

35. Mission Statement Blood stasis Clot Formation Regain LAA function Pump out clot Embolic stroke Design an intracardiac device that detects clots in the LAA accurate safe user friendly

36. Moving Forward mid Oct. 2015 end of Oct. 2015 early Nov. 2015 Mar. 2016 Commit to a modality of sensing technology Finalize our first design (iterative process) Create first working prototype (iterative process) Complete and file a provisional patent Complete final design and prototype end of Sept. 2015

37. Project Clot Team Atriumph Regain LAA function